Gilead's Trodelvy, with Keytruda, cuts breast cancer risk by 35% in trial

Gilead's Trodelvy, in combination with Merck's Keytruda, demonstrated a 35% reduction in the risk of worsening advanced triple-negative breast cancer as an initial treatment, according to Phase 3 trial results. Patients treated with the Trodelvy/Keytruda combination experienced a median progression-free survival of 11.2 months, compared to 7.8 months with chemotherapy and Keytruda; the combination may become a new front-line standard of care for PD-L1 positive tumors, which represent about 40% of triple-negative breast cancers.

Analysis

Gilead Sciences' Trodelvy, when combined with Merck's Keytruda, demonstrated a statistically significant 35% reduction in the risk of disease progression or death in a Phase 3 trial for the initial treatment of advanced PD-L1 positive triple-negative breast cancer (TNBC). The study reported a median progression-free survival (PFS) of 11.2 months for the Trodelvy-Keytruda combination, compared to 7.8 months for patients receiving standard chemotherapy plus Keytruda. Furthermore, the median duration of response was notably longer at 16.5 months for the experimental arm versus 9.2 months for the control group. These findings, presented at the American Society of Clinical Oncology meeting, suggest a high likelihood of this combination becoming a new front-line standard of care for this patient subgroup, which constitutes approximately 40% of the 10% of U.S. breast cancers classified as triple-negative. While overall survival data is still maturing, the current results are highly promising. The side effect profile, including neutropenia (43% in Trodelvy arm vs. 45% in chemo arm) and diarrhea (10% in Trodelvy arm), appears manageable and comparable to existing treatments. This development enhances Trodelvy's market potential, building on its existing approvals for later-line TNBC and other breast cancer types, and supports Gilead's strategy of expanding its oncology franchise.

Key Decisions for Investors

• Investors in Gilead Sciences (GILD) should consider these Phase 3 results as a significant positive development that could drive Trodelvy's adoption in the lucrative first-line triple-negative breast cancer market, potentially leading to upward revisions in revenue forecasts upon regulatory approval.
• For Merck (MRK) investors, this successful combination trial further solidifies Keytruda's foundational role in oncology and its ability to enhance treatment outcomes across various cancer types, reinforcing its market leadership and continued growth trajectory.
• Portfolio managers focused on the biotech and pharmaceutical sectors should monitor the progression towards regulatory submission and potential approval of this combination, as it could shift the treatment paradigm for PD-L1 positive TNBC and impact the competitive landscape for existing and emerging therapies.